When you see positive treatment results, John sees a chance to roast more marshmallows.
Confidence in choosing the right cancer treatment for your patient comes from seeing results. Experience and data have shown ERBITUX use in appropriate patients can deliver the real, tangible results you need to see. Because when you see results, your patient sees hope.
ERBITUX is indicated in combination with platinum-based therapy and fluorouracil (CT) for the first-line treatment of patients with recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck (SCCHN).